A real-life evaluation of two platelet cross-matching programmes for the treatment of patients refractory to platelet transfusions

Nicoletta Revelli, Maria Antonietta Villa, Barbara Olivero, Susanna Bresciani, Marco Flores, Mirella Marini, Mara Nicoletta Pizzi, Daniele Prati, Paolo Rebulla

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background and Objectives: Strategies for overcoming alloimmune refractoriness to random donor platelets are based on the use of compatible platelets selected from large panels of HLA-typed donors or cross-matching (XM). The aim of this study was to review the effectiveness of a platelet XM programme for treating refractory haematological patients at Milan's Policlinico Hospital (PHM) 2002–2014 and Spedali Civili in Brescia (SCB) 2013–2016. Materials and Methods: A commercially available solid-phase antibody detection system was used for platelet antibody detection and XM. Forty-nine alloimmune refractory patients at PHM and 13 at SCB, respectively, received a median [IQR] of 12 [6–13] and 18 [13–15] XM compatible platelet transfusions after the detection of refractoriness. The absolute increases in post-transfusion platelet counts obtained using random, and XM platelets were retrieved from the patients’ hospital records. Results: The critical review at SCB showed that the median [IQR] 1 h post-transfusion increase in platelet counts was 3 × 109/L [1–5] after 47/47 random platelet transfusions, and 10 × 109/L [2–25] after 325/326 XM compatible platelet transfusions. The documentation concerning the outcomes of XM platelet transfusions at PHM was incomplete, and so the findings of the review were inconclusive. Conclusion: This retrospective analysis confirmed the effectiveness of the XM programme at SCB, but revealed defective data collection and retrieval methods at PHM, thus underlining the importance of such methods. The literature review accompanying this retrospective analysis identified a recently described algorithm for ensuring platelet support in refractory patients that optimally integrates the combined use of XM and HLA typing.

Original languageEnglish
Pages (from-to)73-78
JournalVox Sanguinis
Volume114
Issue number1
DOIs
Publication statusPublished - 2019

Fingerprint

Platelet Transfusion
Blood Platelets
Platelet Count
Therapeutics
Tissue Donors
Histocompatibility Testing
Hospital Records
Antibodies
Information Storage and Retrieval
Program Evaluation
Documentation

Keywords

  • HLA
  • platelet transfusion
  • refractoriness

ASJC Scopus subject areas

  • Hematology

Cite this

A real-life evaluation of two platelet cross-matching programmes for the treatment of patients refractory to platelet transfusions. / Revelli, Nicoletta; Villa, Maria Antonietta; Olivero, Barbara; Bresciani, Susanna; Flores, Marco; Marini, Mirella; Pizzi, Mara Nicoletta; Prati, Daniele; Rebulla, Paolo.

In: Vox Sanguinis, Vol. 114, No. 1, 2019, p. 73-78.

Research output: Contribution to journalArticle

@article{196982a30c594e5dbe7f0e426774ef06,
title = "A real-life evaluation of two platelet cross-matching programmes for the treatment of patients refractory to platelet transfusions",
abstract = "Background and Objectives: Strategies for overcoming alloimmune refractoriness to random donor platelets are based on the use of compatible platelets selected from large panels of HLA-typed donors or cross-matching (XM). The aim of this study was to review the effectiveness of a platelet XM programme for treating refractory haematological patients at Milan's Policlinico Hospital (PHM) 2002–2014 and Spedali Civili in Brescia (SCB) 2013–2016. Materials and Methods: A commercially available solid-phase antibody detection system was used for platelet antibody detection and XM. Forty-nine alloimmune refractory patients at PHM and 13 at SCB, respectively, received a median [IQR] of 12 [6–13] and 18 [13–15] XM compatible platelet transfusions after the detection of refractoriness. The absolute increases in post-transfusion platelet counts obtained using random, and XM platelets were retrieved from the patients’ hospital records. Results: The critical review at SCB showed that the median [IQR] 1 h post-transfusion increase in platelet counts was 3 × 109/L [1–5] after 47/47 random platelet transfusions, and 10 × 109/L [2–25] after 325/326 XM compatible platelet transfusions. The documentation concerning the outcomes of XM platelet transfusions at PHM was incomplete, and so the findings of the review were inconclusive. Conclusion: This retrospective analysis confirmed the effectiveness of the XM programme at SCB, but revealed defective data collection and retrieval methods at PHM, thus underlining the importance of such methods. The literature review accompanying this retrospective analysis identified a recently described algorithm for ensuring platelet support in refractory patients that optimally integrates the combined use of XM and HLA typing.",
keywords = "HLA, platelet transfusion, refractoriness",
author = "Nicoletta Revelli and Villa, {Maria Antonietta} and Barbara Olivero and Susanna Bresciani and Marco Flores and Mirella Marini and Pizzi, {Mara Nicoletta} and Daniele Prati and Paolo Rebulla",
year = "2019",
doi = "10.1111/vox.12736",
language = "English",
volume = "114",
pages = "73--78",
journal = "Vox Sanguinis",
issn = "0042-9007",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - A real-life evaluation of two platelet cross-matching programmes for the treatment of patients refractory to platelet transfusions

AU - Revelli, Nicoletta

AU - Villa, Maria Antonietta

AU - Olivero, Barbara

AU - Bresciani, Susanna

AU - Flores, Marco

AU - Marini, Mirella

AU - Pizzi, Mara Nicoletta

AU - Prati, Daniele

AU - Rebulla, Paolo

PY - 2019

Y1 - 2019

N2 - Background and Objectives: Strategies for overcoming alloimmune refractoriness to random donor platelets are based on the use of compatible platelets selected from large panels of HLA-typed donors or cross-matching (XM). The aim of this study was to review the effectiveness of a platelet XM programme for treating refractory haematological patients at Milan's Policlinico Hospital (PHM) 2002–2014 and Spedali Civili in Brescia (SCB) 2013–2016. Materials and Methods: A commercially available solid-phase antibody detection system was used for platelet antibody detection and XM. Forty-nine alloimmune refractory patients at PHM and 13 at SCB, respectively, received a median [IQR] of 12 [6–13] and 18 [13–15] XM compatible platelet transfusions after the detection of refractoriness. The absolute increases in post-transfusion platelet counts obtained using random, and XM platelets were retrieved from the patients’ hospital records. Results: The critical review at SCB showed that the median [IQR] 1 h post-transfusion increase in platelet counts was 3 × 109/L [1–5] after 47/47 random platelet transfusions, and 10 × 109/L [2–25] after 325/326 XM compatible platelet transfusions. The documentation concerning the outcomes of XM platelet transfusions at PHM was incomplete, and so the findings of the review were inconclusive. Conclusion: This retrospective analysis confirmed the effectiveness of the XM programme at SCB, but revealed defective data collection and retrieval methods at PHM, thus underlining the importance of such methods. The literature review accompanying this retrospective analysis identified a recently described algorithm for ensuring platelet support in refractory patients that optimally integrates the combined use of XM and HLA typing.

AB - Background and Objectives: Strategies for overcoming alloimmune refractoriness to random donor platelets are based on the use of compatible platelets selected from large panels of HLA-typed donors or cross-matching (XM). The aim of this study was to review the effectiveness of a platelet XM programme for treating refractory haematological patients at Milan's Policlinico Hospital (PHM) 2002–2014 and Spedali Civili in Brescia (SCB) 2013–2016. Materials and Methods: A commercially available solid-phase antibody detection system was used for platelet antibody detection and XM. Forty-nine alloimmune refractory patients at PHM and 13 at SCB, respectively, received a median [IQR] of 12 [6–13] and 18 [13–15] XM compatible platelet transfusions after the detection of refractoriness. The absolute increases in post-transfusion platelet counts obtained using random, and XM platelets were retrieved from the patients’ hospital records. Results: The critical review at SCB showed that the median [IQR] 1 h post-transfusion increase in platelet counts was 3 × 109/L [1–5] after 47/47 random platelet transfusions, and 10 × 109/L [2–25] after 325/326 XM compatible platelet transfusions. The documentation concerning the outcomes of XM platelet transfusions at PHM was incomplete, and so the findings of the review were inconclusive. Conclusion: This retrospective analysis confirmed the effectiveness of the XM programme at SCB, but revealed defective data collection and retrieval methods at PHM, thus underlining the importance of such methods. The literature review accompanying this retrospective analysis identified a recently described algorithm for ensuring platelet support in refractory patients that optimally integrates the combined use of XM and HLA typing.

KW - HLA

KW - platelet transfusion

KW - refractoriness

UR - http://www.scopus.com/inward/record.url?scp=85058013576&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85058013576&partnerID=8YFLogxK

U2 - 10.1111/vox.12736

DO - 10.1111/vox.12736

M3 - Article

AN - SCOPUS:85058013576

VL - 114

SP - 73

EP - 78

JO - Vox Sanguinis

JF - Vox Sanguinis

SN - 0042-9007

IS - 1

ER -